ArticleScientific reports2025
Fatty acid degradation-related gene signatures as biomarkers for ocular sarcoidosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ocular Sarcoidosis: Contemporary Insights and Future Directions.Romanian journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Sarcoidosis is characterized by the proliferation of noncaseating granulomas and presents as a complex chronic inflammatory disease. It extensively affects multiple organ systems, with 30-60% of patients experiencing ocular complications, predominantly bilateral granulomatous uveitis. Fatty acid degradation, a fundamental metabolic process, is crucial for cellular energy homeostasis, involving the breakdown of fatty acids to produce acetyl-CoA, NADH, and FADH2, which then enter the citric acid cycle and electron transport chain to generate ATP. Despite its importance, the role of fatty acid degradation genes (FADGs) in the pathophysiology of Ocular sarcoidosis (OS) remains unclear. To identify candidates potentially involved in OS, we intersected differentially expressed genes (DEGs) with a curated list of 177 FADGs. Advanced methodologies, including Gene Set Enrichment Analysis (GSEA) and Gene Set Variation Analysis (GSVA), were employed to explore biological functions. Further refinement using Lasso regression and Support Vector Machine-Recursive Feature Elimination (SVM-RFE) allowed for the identification of key hub genes and assessment of their diagnostic potential for OS. Our investigation identified two FADGs, ADH1B and ECI1, closely associated with OS. Functional analyses revealed their involvement in processes such as fatty acid metabolic processes, small molecule catabolic processes, and fatty acid oxidation. Importantly, the diagnostic capabilities of these FADGs demonstrated significant efficacy in distinguishing OS from unaffected states. Through rigorous bioinformatics analyses, this study identifies ADH1B and ECI1 as novel biomarker candidates for OS, elucidating their potential roles in the disease's pathogenesis. These findings offer new insights into the molecular mechanisms underlying OS and highlight the diagnostic potential of FADGs in differentiating OS from unaffected conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.